Validation and Optimization of Host Immunological Bio-Signatures for a Point-of-Care Test for TB Disease.
M. tuberculosis (M. tb)
bio-signature
biomarkers
blood
diagnostic
point of care
validation
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2021
2021
Historique:
received:
18
09
2020
accepted:
18
01
2021
entrez:
15
3
2021
pubmed:
16
3
2021
medline:
6
7
2021
Statut:
epublish
Résumé
The development of a non-sputum-based, point-of-care diagnostic test for tuberculosis (TB) is a priority in the global effort to combat this disease, particularly in resource-constrained settings. Previous studies have identified host biomarker signatures which showed potential, but there is a need to validate and refine these for development as a test. We recruited 1,403 adults presenting with symptoms suggestive of pulmonary TB at primary healthcare clinics in six countries from West, East and Southern Africa. Of the study cohort, 326 were diagnosed with TB and 787 with other respiratory diseases, from whom we randomly selected 1005 participants. Using Luminex
Identifiants
pubmed: 33717089
doi: 10.3389/fimmu.2021.607827
pmc: PMC7952865
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
607827Subventions
Organisme : FIC NIH HHS
ID : D43 TW009127
Pays : United States
Organisme : Medical Research Council
ID : MC_U190071468
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UP_A900_1122
Pays : United Kingdom
Informations de copyright
Copyright © 2021 Mutavhatsindi, van der Spuy, Malherbe, Sutherland, Geluk, Mayanja-Kizza, Crampin, Kassa, Howe, Mihret, Sheehama, Nepolo, Günther, Dockrell, Corstjens, Stanley, Walzl, Chegou and the AE-TBC ScreenTB Consortia.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Mediators Inflamm. 2013;2013:981984
pubmed: 24327799
Thorax. 2016 Sep;71(9):785-94
pubmed: 27146200
Clin Diagn Lab Immunol. 2005 Nov;12(11):1311-6
pubmed: 16275946
PLoS One. 2016 Aug 03;11(8):e0160546
pubmed: 27487181
Nat Microbiol. 2019 May;4(5):748-758
pubmed: 30804546
BMC Infect Dis. 2012 Jan 20;12:10
pubmed: 22260319
Expert Rev Anti Infect Ther. 2011 Apr;9(4):457-69
pubmed: 21504402
J Infect Dis. 2012 May 15;205 Suppl 2:S147-58
pubmed: 22496353
Diagn Microbiol Infect Dis. 2014 Apr;78(4):391-7
pubmed: 24485599
Paediatr Respir Rev. 2007 Jun;8(2):124-33
pubmed: 17574156
S Afr Med J. 2014 Dec;104(12):886-93
pubmed: 26042273
Lancet Infect Dis. 2017 Dec;17(12):1285-1292
pubmed: 28847636
Clin Biochem. 2016 Jan;49(1-2):22-31
pubmed: 26285074
Indian J Med Res. 2013 Mar;137(3):442-4
pubmed: 23640550
Curr Opin Infect Dis. 2009 Apr;22(2):174-82
pubmed: 19283913
Clin Infect Dis. 2016 Apr 15;62(8):995-1001
pubmed: 26908793
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
PLoS One. 2013 May 15;8(5):e64226
pubmed: 23691173
Int J Tuberc Lung Dis. 2011 Dec;15(12):1567-72
pubmed: 22005110
Cochrane Database Syst Rev. 2014 Jan 21;(1):CD009593
pubmed: 24448973
Am J Respir Crit Care Med. 2005 Jun 15;171(12):1430-5
pubmed: 15831840
BMC Infect Dis. 2019 Feb 8;19(1):131
pubmed: 30736743
Lancet Infect Dis. 2017 Dec;17(12):1225-1227
pubmed: 28847637
Eur Respir J. 2012 May;39(5):1269-71
pubmed: 22547737
PLoS One. 2016 May 05;11(5):e0154571
pubmed: 27149626
Tuberculosis (Edinb). 2011 May;91(3):260-7
pubmed: 21459676
Eur Respir J. 2010 Dec;36(6):1488-90
pubmed: 21119209
Oncotarget. 2016 Sep 6;7(36):57581-57592
pubmed: 27557501
PLoS One. 2014 Jul 15;9(7):e102584
pubmed: 25025278